Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 6.6× sales vs its 17.8× historical median P/S.
Fair value ≈ $111.60 · price $41.03 today
Undervalued · 63% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
@Ilovemuffins1 @HarryScrotmmm I'm not speaking for everyone on the board and have done extremely well and you can look me up on all the BO's I have had this year alone- I'll name some for you $TERNS-$APLS-$AKRO tell me what you got?
$OTLK $EYPT $APLS
What a strong week for $OTLK 🚀🔥
"The Office of New Drugs (OND) concluded that substantial evidence of effectiveness has been established and that additional adequate and well-controlled clinical studies are not required for approval of ONS-5010."
EU approval ✅UK approval ✅Commercial launch underway in Germany and the UK ✅FDA appeal confirmed efficacy ✅BLA resubmission announced June 1st and accepted as a Class 1 review (~60 days) ✅Final FDA decision pending ⏳
Connect the dots. The picture is getting pretty clear. 👀🚀
This story keeps getting stronger.💪
$IMMX nice data with 95% CR rate and no relapses, should easily digest the $150M offering
Hat tip to @Sanctuary_Bio, believe this is one of his Winners (on Coffee Call, mentioned you chose it over $APLS and it's 3x'd from Q4 lows)
$APLS Good move here. I have cut 75% of it, and I'm keeping the other 25% in my long-term. I don't think we're going to be losing anything here, but it might as well take a little bit of profit as we continue to ride.
@Bfunk17 @RandandKaren I also owned for 3 years $APLS - sold and bought back even more. You can find my posts there. The BOD finally realized that the best direction for the company to further succede long term and gain market share with a much larger sales force and less expenses was to sell.
$ACAD enterprise value is 0.40X 5-year analyst consensus revenue estimates.
The attachment notes the actual 5-year M&A multiples paid in 11 commercial-stage exits. These 11 peers, all projected to do over $750MM in sales in the year following acquisition just like ACAD, were acquired for 0.86 to 1.25X 5-year revenue forecasts (some even higher).
Because ACAD's multiples reflect enterprise value, the relationship to market cap is not linear as ACAD's 3/31/26 cash is $859MM
The 2nd attachment shows ACAD's fully diluted market cap & enterprise value at $22.40 per share & a hypothetical $46.40 M&A share price if ACAD was acquired for 1.0X 5-year sales, EXCLUDING FY26 GRANTS.
We'd remind investors that $APLS closed at $17.07 per share the day before Biogen announced the acquisition for $41
This is not investment advice. The attachments are simple "what-ifs." We have no idea what ACAD might be worth in a M&A exit.
$APLS Equity Corporate Actions Alert #2026 - 310
Information Regarding the Tender Offer of Apellis Pharmaceuticals, Inc. (APLS)
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-310
The tender offer by Biogen Inc. $BIIB to acquire all of the outstanding common stock of Apellis Pharmaceuticals, Inc. $APLS is scheduled to expire at 11:59 p.m. ET, on May 13, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on May 14, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 13, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (May 14th) and will be suspended effective May 15, 2026.
APLS shareholders will get $41.00 per share plus a non-transferable contingent value right (CVR).
$CPRX M&A valuation as multiples of Year 4 (FY29), 5-year & 10-year revenue estimates versus peer commercial-stage biopharma M&A exits. Peer multiples are calculated using the revenue forecasts prepared by the management/BOD of the acquiree.
$KALV & $APLS also use analyst consensus.
NOTE CPRX is being acquired at one of the highest 10-year multiples (very likely because CPRX is a much more mature commercial-stage bio versus most of the peers).
We're merely sharing our analysis. This is not investment advice.
We cannot think of any peer like CPRX (that sold multiple therapies) except for $XERS which has patent life considerations
$XBI
